Eli Lilly and Novo Nordisk plan to announce new drug pricing deals with the White House, including for their weight loss ...

Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist ...

A rendering of Eli Lilly's planned plant expansion in Pleasant Prairie. The company is preparing for a next phase on a site ...

US pharma group says region’s use of ‘one-way insurance system’ to keep down prices is not fair on the industry ...

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

Eli Lilly invests $3B in a Netherlands plant to produce obesity drug orforglipron, creating new jobs. Read more here.

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Weight loss drugs are set to become a disproportionate share of Lilly's business.

The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A ...